Baxter International Guides Q1, FY23 Adj. EPS Well Below Estimates; To Cut 5% Jobs - Update

RTTNews | 686 days ago
Baxter International Guides Q1, FY23 Adj. EPS Well Below Estimates; To Cut 5% Jobs - Update

(RTTNews) - While reporting financial results for the fourth quarter on Thursday, health care company Baxter International Inc. (BAX) initiated earnings, adjusted earnings and sales growth guidance for the first quarter and for the full-year 2023. The company said the guidance for 2023 reflects a challenging first half of the year due to increased cost of sales resulting from elevated costs of inventory produced in the second half of 2022, reflecting the significant inflationary pressures the company experienced, that will impact earnings when the related inventory is sold in 2023. Baxter expects the impact from these inflationary pressures on its earnings to begin to ease in the second half of the year.

For fiscal 2023, the company now projects earnings in a range of $1.43 to $1.63 per share and adjusted earnings in a range of $2.75 to $2.95 per share on sales growth of 1 to 2 percent on a reported basis and flat to 1 percent on a constant currency basis.

On average, 16 analysts polled by Thomson Reuters expect the company to report earnings of $3.56 per share on sales growth of 1.4 percent to $15.20 billion for the year. Analysts' estimates typically exclude special items.

For the first quarter, the company anticipates earnings in a range of $0.14 to $0.18 per share and adjusted earnings in a range of $0.46 to $0.50 per share on a sales decline of about 3 percent on a reported basis and 1 percent on a constant currency basis.

The Street is looking for earnings of 0.76 per share on a revenue decline of 2.50 percent to $3.61 billion for the quarter.

The company noted that the new operating model design process, which was announced in early January, is expected to be completed by early second quarter, with an updated reporting framework expected to be implemented during the second half of 2023.

In response to the significant macroeconomic challenges Baxter has experienced over the last two years, the company is also in the process of executing a cost reduction program in parallel with its operating model redesign that is expected to be finalized later this quarter.

This initiative and additional actions the company has undertaken to enhance performance are expected to deliver more than $300 million in total savings during 2023. These actions are currently expected to result in a global workforce reduction of less than 5%.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

read more
Baxter International Boosts FY24 Outlook - Update

Baxter International Boosts FY24 Outlook - Update

While reporting financial results for the second quarter on Tuesday, health care company Baxter International Inc. (BAX) raised its earnings, adjusted earnings and sales growth guidance for the full-year 2024. The company also provided outlook for the third quarter.
RTTNews | 142 days ago
Baxter Int'l Launches PERCLOT Absorbable Hemostatic Powder In The US

Baxter Int'l Launches PERCLOT Absorbable Hemostatic Powder In The US

Baxter International Inc. (BAX) announced Monday the launch of PERCLOT Absorbable Hemostatic Powder in the U.S. PERCLOT is a passive, absorbable hemostatic powder that is ready to use and designed for patients with intact coagulation to address mild bleeding.
RTTNews | 521 days ago
Baxter International Q1 Results Top Estimates; Boosts FY23 Adj. EPS Outlook

Baxter International Q1 Results Top Estimates; Boosts FY23 Adj. EPS Outlook

Health care company Baxter International Inc. (BAX) reported Thursday that net income attributable to Baxter for the first quarter declined to $44 million or $0.09 per share from $71 million or $0.14 per share in the prior-year quarter. Excluding items, adjusted earnings for the quarter were $0.59 per share, compared to $0.93 per share in the year-ago quarter.
RTTNews | 609 days ago
Baxter Int'l Announces US Launch Of ZOSYN Premix

Baxter Int'l Announces US Launch Of ZOSYN Premix

Medtech firm Baxter International Inc. (BAX) announced Tuesday the U.S. launch of ZOSYN (piperacillin and tazobactam) Injection. Zosyn premix is indicated for the treatment of multiple infections caused by susceptible bacteria and is available in Baxter's proprietary single-dose Galaxy containers.
RTTNews | 632 days ago
Baxter International Again Slashes FY22 Outlook - Update

Baxter International Again Slashes FY22 Outlook - Update

While reporting financial results for the second quarter on Thursday, health care company Baxter International Inc. (BAX) again lowered its earnings, adjusted earnings and sales growth for the full-year 2022. The company also provided outlook for the third quarter.
RTTNews | 882 days ago